Disease · MONDO_0002050
Comparisons in its trials186
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 186
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Vortioxetine Treatment vs SSRI Treatment: Number of Participants Who Experienced of Intracranial Hemorrhage in Total Follow-up Period | 2 of 22,827 | 25 of 124,950 | 147,777 | NCT05932407 | Trial comparisons |
| FSC Cohort vs AC Cohort: Number of Participants With Any Chronic Obstructive Pulmonary Disease (COPD)-Related Exacerbation | 200 of 1,078 | 674 of 2,923 | 4,001 | NCT01337336 | Trial comparisons |
| Vortioxetine vs Placebo: serious adverse events | 7 of 299 | 4 of 298 | 597 | NCT00672958 | Trial comparisons |
| Venlafaxine Extended Release (ER) vs Venlafaxine Extended Release (ER) Plus Dialogues: serious adverse events | 10 of 269 | 18 of 268 | 537 | NCT00401726 | Trial comparisons |
| Venlafaxine Extended Release (ER) vs Venlafaxine Extended Release (ER) Plus Dialogues: Number of Patients Compliant With Therapy | 248 of 254 | 232 of 239 | 493 | NCT00401726 | Trial comparisons |
| Venlafaxine Extended Release (ER) vs Venlafaxine Extended Release (ER) Plus Dialogues: Number of Patients Responding Very Satisfied on Satisfaction With Depression Care Scale (SDCS) | 160 of 254 | 138 of 239 | 493 | NCT00401726 | Trial comparisons |
| Lumateperone 42 mg vs Placebo: deaths from any cause | 0 of 241 | 0 of 243 | 484 | NCT04985942 | Trial comparisons |
| Lumateperone 42 mg vs Placebo: serious adverse events | 1 of 241 | 1 of 243 | 484 | NCT04985942 | Trial comparisons |
| Sertraline vs Placebo: serious adverse events | 57 of 234 | 63 of 235 | 469 | NCT00078286 | Trial comparisons |
| Electroconvulsive Therapy (ECT) vs Ketamine Infusion: Number of Participants With Treatment Responses Based on the 16-item Quick Inventory of Depressive Symptomatology-Self-Report Scale (QIDS-SR-16) | 70 of 170 | 108 of 195 | 365 | NCT03113968 | Trial comparisons |
| Electroconvulsive Therapy (ECT) vs Ketamine Infusion: deaths from any cause | 0 of 170 | 0 of 195 | 365 | NCT03113968 | Trial comparisons |
| Electroconvulsive Therapy (ECT) vs Ketamine Infusion: serious adverse events | 4 of 170 | 5 of 195 | 365 | NCT03113968 | Trial comparisons |
| Electroconvulsive Therapy (ECT) vs Ketamine Infusion: Number of Participants With Treatment Responses Based on the Montgomery-Åsberg Rating Scale (MADRS) | 70 of 169 | 99 of 195 | 364 | NCT03113968 | Trial comparisons |
| Pregabalin vs Placebo: serious adverse events | 3 of 181 | 1 of 177 | 358 | NCT01432236 | Trial comparisons |
| 60 mg Duloxetine vs 120 mg Duloxetine: Number of Patients With Treatment Emergent Adverse Event | 97 of 167 | 89 of 171 | 338 | NCT02229825 | Trial comparisons |
| 60 mg Duloxetine vs 120 mg Duloxetine: Number of Patients Withdrawn Due to Adverse Events | 11 of 167 | 9 of 171 | 338 | NCT02229825 | Trial comparisons |
| 60 mg Duloxetine vs 120 mg Duloxetine: deaths from any cause | 0 of 167 | 0 of 171 | 338 | NCT02229825 | Trial comparisons |
| 60 mg Duloxetine vs 120 mg Duloxetine: serious adverse events | 6 of 167 | 6 of 171 | 338 | NCT02229825 | Trial comparisons |
| Duloxetine vs Placebo: Number of Participants With Abnormal Laboratory Values - Low Leukocyte Count | 11 of 225 | 0 of 109 | 334 | NCT00406848 | Trial comparisons |
| Ziprasidone vs Placebo: serious adverse events | 1 of 147 | 6 of 147 | 294 | NCT00483548 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0002050/comparisons